Q2 EPS Forecast for Corcept Therapeutics Raised by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research boosted their Q2 2026 earnings estimates for shares of Corcept Therapeutics in a report released on Wednesday, April 2nd. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.68 per share for the quarter, up from their previous forecast of $0.67. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.83 EPS, Q4 2026 earnings at $0.91 EPS, FY2026 earnings at $2.89 EPS, Q1 2027 earnings at $0.59 EPS and FY2027 earnings at $3.75 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). The business had revenue of $181.89 million during the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Several other equities research analysts have also recently weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st. Piper Sandler increased their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a research report on Thursday. StockNews.com downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Truist Financial upped their target price on Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. Finally, HC Wainwright lifted their price target on Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, March 31st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $143.25.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $74.45 on Friday. The company has a market cap of $7.85 billion, a price-to-earnings ratio of 59.09 and a beta of 0.14. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock has a fifty day moving average price of $64.81 and a 200-day moving average price of $56.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in Corcept Therapeutics by 4.5% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 50,996 shares of the biotechnology company’s stock worth $2,360,000 after acquiring an additional 2,216 shares during the last quarter. FMR LLC grew its stake in shares of Corcept Therapeutics by 24.6% in the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after purchasing an additional 269,074 shares during the last quarter. Stifel Financial Corp grew its stake in shares of Corcept Therapeutics by 30.0% in the third quarter. Stifel Financial Corp now owns 88,967 shares of the biotechnology company’s stock worth $4,117,000 after purchasing an additional 20,546 shares during the last quarter. State Street Corp increased its holdings in Corcept Therapeutics by 0.6% in the third quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after purchasing an additional 19,893 shares during the period. Finally, EP Wealth Advisors LLC bought a new position in Corcept Therapeutics during the 3rd quarter worth $302,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the completion of the transaction, the chief executive officer now owns 3,019,411 shares of the company’s stock, valued at $183,912,324.01. This represents a 0.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 163,124 shares of company stock valued at $15,074,318 in the last quarter. Insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.